Moberg Pharma
MOB | ST
Overview
Corporate Details
- ISIN(s):
- SE0011311596 (+3 more)
- LEI:
- 549300XFXK7DVGDRP410
- Country:
- Sweden
- Address:
- Gustavslundsvagen 42, 167 51 Stockholm
- Website:
- https://www.mobergpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Moberg Pharma is a pharmaceutical company focused on the development and commercialization of proprietary medicines. The company's lead product is MOB-015, a novel topical formulation of terbinafine for the treatment of onychomycosis (nail fungus). Marketed under the brand name Terclara®, the product has demonstrated a high cure rate in Phase 3 clinical trials and has achieved market leadership in Sweden and Norway. Moberg Pharma holds market approval for MOB-015 in 13 European countries, with a strategic goal to establish it as the world's leading treatment for nail fungus through direct sales and strategic partnerships in various markets.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Moberg Pharma.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-12 08:00 |
Interim Report
|
Swedish | 645.6 KB | |
| 2025-08-12 08:00 |
Interim Report
|
English | 674.6 KB | |
| 2025-07-03 16:30 |
Major Shareholding Notification
|
Swedish | 10.1 KB | |
| 2025-07-03 10:32 |
Major Shareholding Notification
|
Swedish | 10.9 KB | |
| 2025-06-30 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
|
Swedish | 155.9 KB | |
| 2025-06-30 08:00 |
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Moberg Pharma AB (publ)
|
English | 156.8 KB | |
| 2025-06-25 08:00 |
Board/Management Information
Changes to Moberg Pharma´s Management
|
English | 157.4 KB | |
| 2025-06-25 08:00 |
Board/Management Information
Förändringar i Moberg Pharmas ledningsgrupp
|
Swedish | 157.5 KB | |
| 2025-06-18 10:43 |
Major Shareholding Notification
|
Swedish | 10.5 KB | |
| 2025-06-16 08:00 |
Earnings Release
Terclara market leader also in Norway
|
English | 132.8 KB | |
| 2025-06-16 08:00 |
Regulatory News Service
Terclara nu marknadsledare även i Norge
|
Swedish | 132.5 KB | |
| 2025-06-03 13:30 |
Share Issue/Capital Change
Styrelsen utnyttjar emissions- och återköpsbemyndiganden samt omvandlar aktier …
|
Swedish | 167.9 KB | |
| 2025-06-03 13:30 |
Share Issue/Capital Change
The board of directors exercises authorizations to issue and repurchase C-share…
|
English | 142.6 KB | |
| 2025-05-22 18:45 |
Post-Annual General Meeting Information
Kommuniké från Moberg Pharmas årsstämma den 22 maj 2025
|
Swedish | 173.8 KB | |
| 2025-05-22 18:45 |
Post-Annual General Meeting Information
Bulletin from Moberg Pharma’s AGM on May 22[th], 2025
|
English | 149.8 KB |
Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Moberg Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-11 | Mark Beveridge | Other | Buy | 3,000 | 17,730.00 SEK |
| 2021-11-10 | Mark Beveridge | Other | Buy | 3,000 | 17,310.00 SEK |
| 2021-11-09 | Mark Beveridge | Other | Buy | 5,000 | 29,800.00 SEK |
| 2021-02-10 | Cindy Wong | Other | Buy | 5,000 | 31,675.00 SEK |
| 2021-02-09 | Cindy Wong | Other | Buy | 5,000 | 30,800.00 SEK |
